1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: As momentum grows for the SGLT-2 inhibitor class, can AstraZeneca's Farxiga move into Invokana's slipstream?

Physician Views: As momentum grows for the SGLT-2 inhibitor class, can AstraZeneca's Farxiga move into Invokana's slipstream?

  • January 2014
  • ID: 2005725
  • Format: PDF
  • By Firstword Pharma


Having fully acquired the joint venture that it previously operated with Bristol-Myers Squibb, the forthcoming US launch of Farxiga – approved by the FDA last week – will provide AstraZeneca an early opportunity to demonstrate its credentials in the diabetes market.

A less than straightforward regulatory process will see Farxiga reach the market as the second SGLT-2 inhibitor therapy, following the launch of Johnson & Johnson's Invokana last year.

First-to-market status has typically acted as a key determining factor in the subsequent commercial success of type 2 diabetes treatments, and since being launched, Invokana has delivered a stronger-than-expected performance.

As a result, the SGLT-2 inhibitor class has become rapidly established in the treatment paradigm, but it remains to be seen if Farxiga can find a suitable position in Invokana's slipstream.

While physicians have embraced the SGLT-2 class – with sizeable usage reported in metformin-refractory patients and a recent NEJM survey indicating that "second-line SGLT-2 competition versus DPP-4 inhibitors is a reality," according to analysts at Leerink Swann – it remains to be seen how Farxiga competes with Invokana.

Bearish analysts point to a lack of superiority for AstraZeneca's drug, which coupled with its slower progress to market (due to side-effect concerns) could also limit uptake. Nevertheless, with momentum growing for the SGLT-2 class, there could be an opportunity for AstraZeneca to deliver some early success for its post-JV diabetes portfolio – albeit if ex-partner Bristol-Myers Squibb remains a beneficiary via sizeable royalty payments - Spotlight On: Why AstraZeneca's Farxiga approval is a win-win for Bristol-Myers Squibb.

FirstWord has this week polled US-based endocrinologists the following questions:/Paragraph>

By what percentage they anticipate usage of SGLT-2 inhibitors to increase over the next 12 months?
Whether they would consider treating patients whom had discontinued treatment with Invokana (canagliflozin) - due to side-effect issues - with a second SGLT-2 inhibitor?
Whether they plan to prescribe Farxiga (dapaglifozin) in preference to Invokana and the reasons for doing so?
How significant superiority data for Invokana versus Januvia (sitagliptin) has been in driving usage of Invokana to date?
To what extent Farxiga's labelling – non-black-box warning relating to low cases of bladder cancer – will have on anticipated usage of the drug?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on